Last reviewed · How we verify
SURGICEL®
At a glance
| Generic name | SURGICEL® |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery (NA)
- GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery (NA)
- Evaluation of Hemostatic Agents in Partial Nephrectomy (NA)
- NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery (NA)
- A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery (PHASE3)
- Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial (NA)
- Effectiveness of Surgical Procedures for Acute Cranial Expansion in Traumatic Brain Injury
- Evaluation of the Effect of SURGICEL® Powder in TKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SURGICEL® CI brief — competitive landscape report
- SURGICEL® updates RSS · CI watch RSS
- Cairo University portfolio CI